Heterogeneity in expression of human leukocyte antigens and melanoma- associated antigens in advanced melanoma

Journal of Cellular Physiology

Volumn 182, Issue 3, 2000, Pages 332-338

  Ohnmacht, Galen A ^a   Marincola, Francesco M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN; MELANOMA ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGENIC VARIATION; CELL HETEROGENEITY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNOLOGY;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKOCYTES; MELANOMA; SKIN NEOPLASMS;

EID: 0033984089     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200003)182:3<332::AID-JCP3>3.0.CO;2-Z     Document Type: Review

References (96)

1. Alpan RS, Zhang M, Pardee AB. 1996. Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res 56:4358-4361.
2. 2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520-529.
3. Bernards R, Dessain SK, Weinberg RA. 1986. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47:667-674.
4. Bicknell DC, Rowan A, Bodmer WF. 1994. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 91:4751-4756.
5. Blanchet O, Bourge JF, Zinszer H, Tatari Z, Degos L, Paul P. 1991. DNA binding of regulatory factors interacting with MHC class-I gene enhancer correlates with MHC-class-I transcriptional level in class-I-defective cell lines. Int J Cancer Suppl 6:138-145.
6. Blanchet O, Bourge JF, Zinszner H, Israel A, Kourilsky P, Dausset J, Degos L, Paul P. 1992. Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc Natl Acad Sci USA 89:3488-3492.
7. Boon T, Coulie PG, Van den Eynde B. 1997. Tumor antigens recognized by T cells. Immunol Today 18:267-268.
8. Brower RC, England R, Takeshita T, Kozlowski S, Margulies DH, Berzofsky JA, Delisi C. 1994. Minimal requirements for peptide mediated activation of CD8+ CTL. Mol Immunol 31:1285-1293.
9. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. 1996. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer [see comments]. Nat Genet 13:210-213.
10. Chen SJ, Wang SS, Lu CW, Chao Y, Lee FY, Lee SD, Wu SL, Cherng KL, Lo KJ. 1994. Clinical value of tumour markers and serumascites albumin gradient in the diagnosis of malignancy-related ascites. J Gastroenterol Hepatol 9:396-400.
11. Chen Y-T, Stockert E, Tsang S, Coplan KE, Old LJ. 1995. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 92:8125-8129.
12. Christinck ER, Luscher MA, Barber BH, Williams DB. 1991. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352:67-70.
13. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J Sci Am 3:37-44.
14. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL. 1998a. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother Emphasis Tumor Immunol 21:27-31.
15. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM. 1998b. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75:517-524.
16. Cormier JN, Panelli MC, Hackett JA, Bettinotti M, Mixon A, Wunderlich J, Parker L, Restifo NP, Ferrone S, Marincola FM. 1999. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 80:781-790.
17. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J Exp Med 180:35-42.
18. Cox AL. Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719.
19. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335-340.
20. Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF. 1991. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells: evidence for restriction by a dominant HLA-A allele. J Immunol 146:1692-1699.
21. Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, Bordignon C, Natali PG, Traversari C. 1998. High homogeneity of MAGE, BAGE, GAGE, Tyrosinase and Melan-A.MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 77:200-204.
22. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. 1996. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 93:7149-7153.
23. de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. 1997. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 57:3223-3229.
24. Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttitta F, Mulshine J, Bunn P. 1985. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 161:1135-1151.
25. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. 1991. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 87:284-292.
26. Feltner DE, Cooper M, Weber J, Israel MA, Thiele CJ. 1989. Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene. J Immunol 143:4292-4299.
27. Ferrone S, Marincola FM. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol.Today 16:487-494.
28. Foa R, Guarini A, Gansbacher B. 1992. IL2 treatment for cancer: from biology to gene therapy. Br J Cancer 66:992-998.
29. Francke U, Pellegrino MA. 1977. Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. Proc Natl Acad Sci USA 74:1147-1151.
30. Goodfellow PN, Jones EA, Van Heyningen V, Solomon E, Bobrow M, Miggiano V, Bodmer WF. 1975. the beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature 254:267-269.
31. Henseling U, Schmidt W, Scholer HR, Gruss P, Hatzopoulos AK. 1990. A transcription factor interacting with the class I gene enhancer is inactive in tumorigenic cell lines which suppress major histocompatibility complex class I genes. Mol Cell Biol 10:4100-4109.
32. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. 1998. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 101:2720-2729.
33. Hicklin DJ, Marincola FM, Ferrone S. 1999. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178-186.
34. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH. 1992. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry [see comments]. Science 255:1261-1263.
35. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142-147.
36. Johnsen A, France J, Sy MS, Harding CV. 1998. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 58:3660-3667.
37. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. 1999. Downregulation of HLA class I antigen processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154: 745-754.
38. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. 1995. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 55:5191-5194.
39. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352.
40. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968.
41. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. 1996. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 73:148-153.
42. Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA. 1996. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 23: 1181-1188.
43. Lenardo M, Rustgi AK, Schievella AR, Bernards R. 1989. Suppression of MHC class I gene expression by N-myc through enhancer inactivation. EMBO J 8:3351-3355.
44. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-649.
45. Lethe B, van der Bruggen P, Brasseur F, Boon T. 1997. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res 7(Suppl 2):S83-S88.
46. Ljunggren HG, Karre K. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants: analysis of the mechanism. J Exp Med 162:1745-1759.
47. Lopez-Botet M, Moretta L, Strominger J. 1996. NK-cell receptors and recognition of MHC class I molecules. Immunol Today 17:212-214.
48. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. 1991. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 88:282-289.
49. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int J Cancer 63:883-885.
50. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restifo NP, Herlyn M, Rosenberg SA. 1994a. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153:1225-1237.
51. Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O'Dea T, Fetsch P, Yannelli J, Restifo NP, Mule JJ, Rosenberg SA. 1994b. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 16:13-23.
52. Marincola FM, Shamamian P, Rivoltini L, Salgaller ML, Reid J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR. 1996. HLA associations in the anti-tumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol 18:242-252.
53. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. 1999. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol (in press)
54. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182:75-85.
55. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332.
56. Old LJ, Chen YT. 1998. New paths in human cancer serology. J Exp Med 187:1163-1167.
57. Ottesen SS, Kieler J, Christensen B. 1987. Changes in HLA A, B, C expression during "spontaneous" transformation of human urothelial cells in vivo. Eur J Cancer Clin Oncol 23:991-995.
58. Pena J, Alonso C, Solana R, Serrano R, Carracedo J, Ramirez R. 1990. Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur J Immunol 20:2445-2448.
59. Porgador A, Mandelboim O, Restifo NP, Strominger JL. 1997. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci USA 94:13140-13145.
60. Redondo M, Ruiz-Cabello F, Concha A, Cabrera T, Perez-Ayala M, Oliva MR, Garrido F. 1991. Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res 51:2463-2468.
61. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. 1993a. Identification of human cancers deficient in antigen processing. J Exp Med 177:265-272.
62. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA. 1993b. Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of Major Histocompatibility Complex. J Immunother Emphasis Tumor Immunol 14:182-190.
63. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. 1996. The loss of functional β2-microglobulin in metastatic melanomas from five patients undergoing immunotherapy. J Natl Cancer Inst 88:100-108.
64. Riker A, Kammula US, Panelli MC, Wang E, Abati A, Fetsch P, Lee K-H, Steinberg SM, Rosenberg SA, Marincola FM. 1999. Immune selection following antigen specific immunotherapy of melanoma. Surgery 126:112-120.
65. Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM. In Press. Threshold levels of gene expression of the melanoma antigen gp100 determine tumor cell recognition by cytotoxic T-lymphocytes. Int J Cancer.
66. Rosenberg SA. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182.
67. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492.
68. Rosenberg SA, Spiess P, Lafreniere R. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321.
69. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson, C, Carter C, Block S, Schwartzentruber DJ, Wei JP, White DE. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 319:1676-1680.
70. Rosenberg SA. 1998. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alpha-26. J Clin Oncol 17(3):968-975.
71. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis SJ, Belich MP, Croom-Carter D, Lee S, Burrows SR, Trowsdale J, Moss DJ, Rickinson AB. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporter and HLA-class I antigen expression. Eur J Immunol 25:1374-1384.
72. Ruiz-Cabello F, Perez-Ayala M, Gomez O, Redondo M, Concha A, Cabrera T, Garrido F. 1991. Molecular analysis of MHC-class-I alterations in human tumor cell lines. Int J Cancer Suppl 6:123-130.
73. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll D, Simons JW. 1995. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87: 280-285.
74. Scheibenbogen C, Weyers I, Ruiter D, Willhauck M, Bittinger A, Keilholz U. 1996. Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J Immunother Emphasis Tumor Immunol 19:375-380.
75. Schild H, Rotzschke O, Kalbacher H, Rammensee HG. 1990. Limit of T cell tolerance to self proteins by peptide presentation. Science 247:1587-1589.
76. Schrier PI, Peltenburg LT. 1993. Relationship between myc oncogene activation and MHC class I expression. Adv Cancer Res 60:181-246.
77. Seigler HF, Kremer WB, Metzgar RS, Ward FE, Haung AT, Amos DB. 1971. HL-A antigenic loss in malignant transformation. J Natl Cancer Inst 46:577-584.
78. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, Huber C. 1996. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 2:1427-1433.
79. Singal DP, Ye M, Ni J, Snider DP. 1996. Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett 50:149-154.
80. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565-571.
81. Tomita Y, Matsumoto Y, Nishiyama T, Fujiwara M. 1990a. Reduction of major histocompatibility complex class I antigens on invasive and high-grade transitional cell carcinoma. J Pathol 162:157-164.
82. Tomita Y, Nishiyama T, Fujiwara M, Sato S. 1990b. Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. Br J Cancer 62:354-359.
83. Urban JL, Van Waes C, Schreiber H. 1984. Pecking order among tumor-specific antigens. Eur J Immunol 14:181-187.
84. Urban JL, Kripke ML, Schreiber H. 1986. Stepwise immunologic selection of antigenic variants during tumor growth. J Immunol 137:3036-3041.
85. Van't Veer LJ, Beijersbergen RL, Bernards R. 1993. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa. EMBO J 12:195-202.
86. Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI. 1988. c-myc down-regulates class I HLA expression in human melanomas. EMBO J 7:1023-1029.
87. Versteeg R, Kruse-Wolters KM, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, Ruiter DJ, Schrier PI. 1989. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med 170:621-635.
88. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S. 1998. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 58:737-742.
89. Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S. 1999. Selective human leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 190:205-215.
90. Wei ML, Cresswell P. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443-446.
91. Wettstein PJ, Bailey DW. 1982. Immunodominance in the immune response to "multiple" histocompatibility antigens. Immunogenetics 16:47-58.
92. White RL. 1998. Excess risk of colon cancer associated with a polymorphism of the APC gene? Cancer Res 58:4038-4039.
93. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170:797-810.
94. Wucherpfennig KW, Strominger JL. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705.
95. Yewdell JW, Bennink JR. 1990. The binary logic of antigen processing and presentation to T cells. Cell 62:203-206.
96. York IA, Rock KL. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14: 369-396.